SCM
BLTE

Soleus Capital Management’s Belite Bio BLTE Stock Holding History

Soleus Capital Management’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-40,354
Closed -$6.46M – 96
2025
Q4 		$6.46M Sell
40,354
-169,646
-81% -$20.1M 0.24% 62
2025
Q3 		$15.5M Buy
+210,000
New +$13.8M 0.78% 34

Other funds holding BLTE

DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Soleus Capital Management's BLTE Position: Q1 2026 in Review

Soleus Capital Management sold out of Belite Bio (BLTE) in Q1 2026, closing a stake of 40,354 shares — an estimated $6.46M sold.

Soleus Capital Management first reported a position in BLTE in Q3 2025 and held it in 2 quarters. The position peaked at $15.5M in Q3 2025. 75 funds tracked by Wall St. Rank hold BLTE as of Q1 2026.

  • Soleus Capital Management reported no remaining Belite Bio position as of Q1 2026 after selling out during the quarter.
  • Soleus Capital Management sold 40,354 Belite Bio shares in Q1 2026, an estimated $6.46M.
  • Soleus Capital Management first reported a position in Belite Bio in Q3 2025 and held it in 2 quarters.
  • Soleus Capital Management's Belite Bio position peaked at $15.5M in Q3 2025.
  • 75 funds tracked by Wall St. Rank held Belite Bio as of Q1 2026.

Based on Soleus Capital Management's 13F filing for Q1 2026, filed 14 May 2026.